02:31:35	1	MS. STERK: Objection. Vague. Calls for speculation.
	2	THE WITNESS: With only looking at one month, I can't
	3	say whether it was high or not.
	4	BY MR. LiMANDRI:
02:31:45	5	Q Okay. Let's go then to Exhibit 2405. Before we do
	6	that, let me ask one more question about 2212, the invoice
	7	we just looked at. You mentioned you thought there was an
	8	accreditation by PPFA in 2012. Do you know if that was
	9	before or after this time frame of this invoice, which was
02:32:28	10	sent on September 5th, 2012?
	11	A I know that it was before. I remember it was in
	12	June of 2012, the accreditation.
	13	Q Okay. Thank you. Do you have any idea whether or
	14	not anyone from the accreditation team actually reviewed any
02:32:45	15	of PPMM's invoices that were sent to Stem-Express when PPFA
	16	accreditors conducted their review?
	17	MS. STERK: Objection. Calls for speculation. Vague.
	18	THE WITNESS: I don't know. They there was review
	19	of financial statements and that sort of thing, but I have
02:33:07	20	no idea if it included any of this.
	21	BY MR. LiMANDRI:
	22	Q Do you know who, if anyone, from PPMM would know
	23	whether or not the accreditors from PPFA reviewed actual
	24	PPMM invoices to Stem-Express?
02:33:27	25	MS. STERK: Objection. Calls for speculation.

02:33:29	1	THE WITNESS: I don't know if the financial department
	2	kept copies of specifically what PPFA reviewed or not.
	3	BY MR. LiMANDRI:
	4	Q Okay. So you don't know who at PPMM would know
02:33:42	5	that information?
•	6	A Not specifically. Somebody in the accounting
	7	department.
	8	Q Okay. Going back then to 2405. Have you seen this
	9	document before, Dr. Furgerson?
02:34:02	10	A No.
	11	Q Okay. It's I'll represent my understanding is
	12	it's a Stem-Express brochure, referring to the last page.
	13	And I don't know if it would refresh your recollection at
	14	the bottom of the second page, it's got a quote that
02:34:18	15	purports to be from you. It says, our partnership with
	16	Stem-Express is beneficial in a number of ways. First, it
	17	allows us to contribute to life-saving research that is
	18	advancing, diagnostic, and medical care. Second,
	19	Stem-Express has a plug-in solution that allows us to add
02:34:41	20	additional clinics quickly. Lastly, I feel confident that
	21	our patients anonymity is secure through their strict
	22	protocols and practices. That's attributed to Dr. Dorothy
	23	Furgerson, Mar Monte.
	24	Had you seen this particular page with that particular
02:35:05	25	quote that I just read prior to today?

02:35:08	1	MS. STERK: Objection. Vague.
	2	THE WITNESS: I had not seen the page, no.
	3	BY MR. LiMANDRI:
	4	Q Okay. Do you recall providing Plan do you
02:35:14	5	recall providing Stem-Express with permission to use your
	6	quote in its promotional brochure?
	7	MS. STERK: Objection. Vague. Lacks foundation.
	8	THE WITNESS: No.
	9	BY MR. LiMANDRI:
02:35:27	10	Q Do you recall actually making this quote?
	11	MS. STERK: Objection. Lacks foundation.
	12	THE WITNESS: I did not write this quote.
	13	BY MR. LiMANDRI:
	14	Q Do you know who did?
02:35:37	15	A Someone at Stem-Ex, Stem-Express.
	16	Q Okay. Did they get your permission to use it?
	17	MS. STERK: Objection. Vague.
	18	THE WITNESS: Yes. They got my permission to use it,
	19	but not specifically in a brochure.
02:35:50	20	BY MR. LiMANDRI:
	21	Q Okay. What understanding did you have, if any, at
	22	the time you gave them permission to use your quote as to
	23	how they would use it?
	24	A My understanding was that it would be used at one
02:36:03	25	meeting or conference. And my impression was that it would

02:36:07	1	be put on a poster at a booth at a meeting or conference.
	2	Q I see. Do you know if it was put on a poster at a
	3	booth at a meeting or conference?
	4	A I do not.
02:36:19	5	Q Do you know which meeting or conference they
	6	intended to use your quote?
	7	A No, I do not.
	8	Q Do you know if it was a meeting or conference you
	9	attended?
02:36:31	10	A I I think it would not be a meeting I had
	11	attended.
	12	Q Would you typically attend meetings or conferences
	13	where other Planned Parenthood executives would be in
	14	attendance?
02:36:45	15	MS. STERK: Objection. Vague. Compound.
	16	THE WITNESS: Yes.
	17	BY MR. LiMANDRI:
	18	Q What would be the types of conferences you would
	19	attend on any type of a regular basis where there would be
02:36:53	20	other Planned Parenthood executives in attendance?
	21	MS. STERK: Objection. Vague.
	22	THE WITNESS: We had an annual meeting called the
	23	National Medical Conference.
	24	BY MR. LiMANDRI:
02:37:05	25	Q Okay. In looking at this brochure now, does it

02:37:09	1	refresh your recollection as to what meeting it was used at
	2	by Stem-Express?
	3	MS. STERK: Objection. Asked and answered.
	4	THE WITNESS: No. I don't think I knew what meeting.
02:37:22	5	BY MR. LiMANDRI:
	6	Q Okay. If it was used at a NAF conference, do you
	7	know who would typically attend be expected to attend NAF
	8	conferences?
	9	MS. STERK: Objection. Calls for speculation. Vague.
02:37:36	10	THE WITNESS: No.
	11	BY MR. LiMANDRI:
	12	Q Okay. Have you ever attended a NAF conference?
	13	A No.
	14	Q Okay. Would you NAF, you understand I'm sure,
02:37:39	15	stands for National Abortion Federation, correct?
	16	A Yes, I know that.
	17	Q So you would expect people involved in some aspect
	18	of the abortion industry to attend a NAF conference, would
	19	you not?
02:37:53	20	MS. STERK: Objection. Calls for speculation. Vague.
	21	THE WITNESS: I'm aware that some physicians who
	22	perform abortion attended NAF conferences.
	23	BY MR. LiMANDRI:
	24	Q Okay. Did Stem-Express indicate to you that they
02:38:08	25	intended to use your quote at a conference that would be

02:38:13	1	attended by abortion doctors?
	2	MS. STERK: Objection. Calls for speculation. Lack of
	3	foundation. Vague.
	4	THE WITNESS: I don't believe they characterized or
02:38:21	5	told me what meeting or conference it would be used at.
	6	BY MR. LiMANDRI:
	7	Q Did you have any understanding or expectation of
	8	what type of conference it would be used at?
	9	A No.
02:38:32	10	Q On the first page of this pamphlet, it says, your
	11	clinic can advance medical biomedical research. And it
	12	says bullet point that says financially profitable.
	13	Do you have an understanding of what they mean by that?
	14	MS. STERK: Objection. Calls for speculation.
02:38:54	15	THE WITNESS: I do not.
	16	BY MR. LiMANDRI:
	17	Q It also, says easy to plug easy to implement
	18	plug-in solution. Do you have an understanding of what that
	19	means?
02:39:03	20	A I do not.
	21	Q Because they use that phrase, I believe, in the
	22	quote that they attributed to you. Where it says,
	23	Stem-Express has a plug-in solution that allows us to add
	24	additional clinics quickly. Do you know what that means?
02:39:23	25	A I don't I don't know now and I don't think I

02:39:26	1	knew then.
	2	Q Okay. And when it says IRB certified consents, did
	3	you know what institutional review board had to review the
	4	consents?
02:39:40	5	MS. STERK: Objection. Lacks foundation. Calls for
	6	speculation.
	7	BY MR. LiMANDRI:
	8	Q Looking at the first page still. It says IRB
	9	consents. Do you know what that means?
02:39:49	10	MS. STERK: Objection. Calls for speculation.
	11	THE WITNESS: It says to me that they would provide
	12	consent forms that had been reviewed by an IRB.
	13	BY MR. LiMANDRI:
	14	Q Okay. You don't know what IRB they're referring
02:40:03	15	to?
	16	A No.
	17	Q Did you understand that they were going to use this
	18	brochure or poster with your quote in order to seek to
	19	obtain more potential sources of fetal tissue?
02:40:16	20	MS. STERK: Objection. Lacks foundation. Calls for
	21	speculation.
	22	THE WITNESS: Yes, I understood that that's what they
	23	were trying to do.
	24	BY MR. LiMANDRI:
02:40:25	25	Q Okay. Why is it you felt that you wanted to lend

02:40:32	1	whatever prestige associated with your name to their and
	2	title to their effort to secure more potential sources of
	3	fetal tissue?
	4	MS. STERK: Objection. Lacks foundation. Vague.
02:40:47	5	THE WITNESS: I felt they were doing societal good by
	6	increasing medical research, and I supported that.
	7	BY MR. LiMANDRI:
	8	Q Okay. At the bottom of the third page beginning at
	9	the top under the first sentence under advancing biomedical
02:41:14	10	research together, it says, join the Stem-Express partner
	11	program that fiscally rewards clinics.
	12	Do you have an understanding as to what they meant by
	13	"fiscally rewards clinics"?
	14	MS. STERK: Objection. Calls for speculation.
02:41:29	15	THE WITNESS: No, I don't.
	16	BY MR. LiMANDRI:
	17	Q Okay. And under the last paragraph on the same
	18	page, easy to implement program, plus financial benefits.
	19	It says, Stem-Express promotes global biomedical research
02:41:44	20	while also providing a financial benefit to your clinic.
	21	Do you have any understanding as to what they meant
	22	when they talk about providing a financial benefit to
	23	clinics?
	24	MS. STERK: Objection. Calls for speculation.
02:41:58	25	THE WITNESS: No, I don't.